Rank: 22 (Previous rank: N/A)
2006 Revenues (millions): $159.63
Headquarters: Silver Spring, MD
Get quote: UTHR
United Therapeutics' lead product, Remodulin, treats high blood pressure in the pulmonary artery. Patients with chronic and life threatening illnesses, such as cancer, cardiovascular and infectious diseases, also rely on medicines developed by this biotechnology company. UTHR is developing an oncology drug for ovarian cancer.
See more FSB 100 data for United Therapeutics